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236Objective: One established predictor for failure of surgical ablation for atrial fibrillation is increased left atrial
size. Surgeon perception is that surgical ablation in these patients is ineffective and should not be performed.
The purpose of this study was to determine whether a larger left atrial size carries a prohibitive risk for failure
and embolic events after surgical ablation.
Methods: In patients undergoing surgical ablation without left atrial reduction (N ¼ 373), left atrial size was
measured via transthoracic echocardiography within 6 months before surgery. Large (>5.5 cm; n ¼ 83) and
small (5.5 cm; n ¼ 290) left atrial size groups were compared on outcomes.
Results: Patients in the large left atrium group were younger (P ¼ .02) and had lower operative risk
(European System for Cardiac Operative Risk Evaluation, P ¼ .01), but they were not different in type
(P ¼ .51) or duration of atrial fibrillation (P ¼ .93). The large left atrium group was less likely to be in sinus
rhythm at 1 year (86% vs 93%, P ¼ .04), but there was no difference in sinus rhythm without
antiarrhythmic drugs (77% vs 85%, P ¼ .10). By 2 years, the large and small left atrium groups were similar
in sinus rhythm (85% vs 90%,P¼ .35). Freedom from embolic strokewas similar (P¼ .70) despite the majority
of patients not taking anticoagulation at 1 year.
Conclusions: The large left atrium group had acceptable return to sinus rhythm and sinus rhythm without
antiarrhythmic drugs. The embolic stroke rate was low despite the majority of patients not taking anticoagula-
tion. If patients are managed appropriately post-ablation, left atrial size should not be a discouragement when
evaluating surgical candidates with atrial fibrillation. (J Thorac Cardiovasc Surg 2014;147:236-41)The first Cox-Maze procedure for surgical ablation of atrial
fibrillation (AF) was performed more than 25 years ago, and
despite some changes in the lesion set, the basic concepts of
the procedure have remained the same. However, the advent
of new technology has provided an opportunity for the
lesions to be completed with alternate energy sources,
primarily cryothermia and radiofrequency, allowing for
less time spent on bypass and a less tedious procedure.1-5
Current long-term results for surgical ablation of AF
range from 70% to 90% depending on whether any
modifications to the original lesion set were made,
especially in patients with nonparoxysmal AF.2,6 Along
with the reporting of results, many investigators have
reported the predictors of failure in their cohort of
patients.7-11 A consistent finding for most investigators has
been the size of the left atrium (LA) at the time of surgery,
such that the larger the LA (>5.5 cm) the higher the ratee Inova Heart and Vascular Institute, Falls Church, Va.
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The Journal of Thoracic and Cardiovascular Surgof failure.7-11 As a result, the perception among surgeons
is that surgical ablation in patients with an enlarged LA is
highly ineffective and should not be performed. There are
no clear data on whether certain LA dimensions are
related to results and thereby prohibit surgical ablation.
The purpose of this study was to explore the
variables associated with failure of the full Cox-Maze
procedure as originally designed.1,12 Specifically, we
sought to (1) examine the traditional predictors of failure
(age, gender, left atrial size, and duration of AF) at
12 months to determine the relevancy when newer
ablative devices are used; and (2) determine whether
preoperative left atrial size greater than 5.5 cm carries a
risk for recurrent atrial arrhythmia and embolic events
after surgical ablation.
MATERIALS AND METHODS
This was a cohort study whereby all patients with preoperative left atrial
size measurement who underwent surgical ablation without left atrial
reduction surgery between January 2005 and August 2012 were followed
prospectively (N¼ 518). A total of 373 consecutive patients were available
for analysis with follow-up data at 1 year. There were 145 patients who
did not complete 1-year follow-up, in whom there were 6 operative deaths
(<30 days; 1.2%) and 21 deaths during the first year of follow-up.
All patients were included in our unique AF registry, which stores
detailed information collected prospectively about the surgical ablation
case including preoperative and postoperative data. Rhythm status using
electrocardiography and 24-hour Holter, and clinical follow-up were
collected and verified at 3, 6, 9, 12, 18, and 24months and yearly thereafter.
The definition for success or failure of surgical ablation was according toery c January 2014
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CI ¼ confidence interval
LA ¼ left atrium
OR ¼ odds ratio
SR ¼ sinus rhythm
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merged with data from the Society of Thoracic Surgeons database at the
Inova Heart and Vascular Institute. Left atrial size was measured via
transthoracic echocardiography within 6 months before surgery. All
patients underwent standard transthoracic examination using the routine
protocols from our accredited cardiac diagnostics department. The
anteroposterior left atrial diameter was measured from the parasternal
long-axis view using M-mode measurements. All perioperative outcomes
were determined according to the Society of Thoracic Surgeons database
definitions. This study was approved by the institutional review board at
the Inova Heart and Vascular Institute, and a waiver of patient consent
for our research program was obtained (studies 06.022 and 12.055).
Surgical Ablation Technique
Surgical ablation was performed by multiple surgeons. In 87% of pa-
tients, the complete Cox-Maze III/IV lesion set was performed as described
previously.7,12 In the remaining 13% of patients, pulmonary vein isolation
or limited left-sided surgical ablation was performed in patients presenting
with intermittent AF (paroxysmal or persistent AF). Cryothermia only
(Medtronic, Inc, Minneapolis, Minn) was used as the sole energy source
in 44% of patients, bipolar radiofrequency was used in 10% of patients,
and a combination of cryothermia and bipolar radiofrequency (Atricure,
West Chester, Ohio) was used in the remaining 46% of patients.
Statistical Analysis
Continuous data are presented as mean  standard deviation, and
categorical data are presented as frequency (percent) unless otherwise
noted. All analyses were conducted using SPSS version 17.0 (SPSS Inc,
Chicago, Ill). Group comparisons for perioperative and rhythm outcomes
were conducted in 2 groups based on left atrial size: large (>5.5 cm) and
small (5.5 cm). There are multiple publications related to left atrial
size as a predictor for failure in electrophysiology and surgical literature.
The left atrial sizes mentioned are usually between 5 and 6 cm.14 Therefore,
we chose 5.5 cm as the reference cutoff.
Categorical variables were compared using the chi-square test or Fisher’s
exact test, andcontinuousmeasureswere examinedwithStudent’s independent
samples t test orMann–WhitneyU test as appropriate, based on parametric test
assumptions. The impact of left atrial size (as a continuousmeasure) on rhythm
status also was analyzed using univariate logistic regression. Failure in these
analyses was defined as recurrence of AF at the time point of interest. In addi-
tion, multivariate logistic regression was conducted to examine the predictors
of failure at 1year in all patients andwithin the largeLAgrouponly.The factors
included in this model were age, gender, diabetes, ejection fraction (%), pe-
ripheral vascular disease, hypertension, additive European System for Cardiac
OperativeRisk Evaluation, duration ofAF (years), ablation energy source, sur-
gical ablation lesion set (full vs limited), number of concomitant surgeries, and
left atrial size as a continuous variable (for the full sample analysis only).RESULTS
Patient Characteristics
Since 2005, therewere 373 patients with surgical ablation
and 1-year follow-up. The large LA group (>5.5 cm)The Journal of Thoracic and Caincluded 83 patients, and the small LA group (5.5 cm)
included 290 patients. The large LA group was younger
(P ¼ .02), had lower operative risk (European System for
Cardiac Operative Risk Evaluation, P¼ .01), had fewer pa-
tients with diabetes mellitus (P ¼ .02) and hypertension
(P ¼ .02), had lower ejection fraction (P ¼ .03), and had
significantly more concomitant mitral valve surgery
(P< .001; Table 1). There were no differences in type or
duration of AF between the groups (P ¼ .93).
Perioperative Morbidity
Between January 2005 and August 2012, a total of 518
patients with preoperative transthoracic echocardiography
and left atrial size measurements underwent a surgical abla-
tion procedure. A total of 145 patients were excluded from
the analysis, in whom there were 6 operative deaths (<30
days; 1.2%) and 21 deaths during the first year of follow-
up, leaving 373 patients for the final analysis. Periopera-
tively, the large LA group was not different from the small
LA group on permanent stroke (0% vs 0.7%, P ¼ 1.00),
prolonged ventilation greater than 24 hours (5% vs 6%,
P ¼ .80), pneumonia (1% vs 3%, P ¼ .69), reoperation
for bleeding (1% vs 5%, P ¼ .32), new renal failure (4%
vs 2%, P ¼ .38), new renal failure requiring dialysis (2%
vs 1%, P ¼ .31), and readmission within 30 days (10%
vs 12%, 0.70).
Sinus Rhythm Outcomes
Results indicated that the large LA group was less likely
to be in sinus rhythm (SR) at 1 year compared with the small
LA group (86% vs 93%, P ¼ .04; Table 2). However, the
large LA group was not different from the small LA group
in terms of SR without class I/III antiarrhythmic drugs at
1 year (77% vs 85%, P ¼ .10). By 2 years, the large LA
group was similar to the small LA group in SR overall
(85% vs 90%, P ¼ .35) and SR without antiarrhythmic
drugs (73% vs 81%, P ¼ .28). Furthermore, at 1 year,
patients with left atrial size 7.5 cm or greater (n ¼ 7)
showed reasonable rates of SR (86%) and SR without
antiarrhythmic drugs (71%). The large LA group did not
require more cardioversions (23% vs 18%, P¼ .34) during
follow-up.
The incidence of embolic stroke was low in both the
small (n ¼ 5, 1.7%) and large (n ¼ 1, 1.2%) LA groups.
Freedom from embolic stroke during follow-up was found
to be similar across LA groups (log rank ¼ 0.15, P ¼ .70;
Figure 1) despite the majority of patients in both the small
and large LA groups not taking warfarin at 12 months
(67% vs 61%, P ¼ .35). The majority of patients who
remained on warfarin at 12 months were treated with anti-
coagulation for non-AF indications (ie, deep vein throm-
bosis, pulmonary embolism), and this did not differ
significantly across LA groups (55% vs 71%, P ¼ .14;
Table 2).rdiovascular Surgery c Volume 147, Number 1 237
TABLE 1. Patient characteristics
Small LA
(n ¼ 290)
Large LA
(n ¼ 83)
P
value
Age, y 65.3  11.0 61.9  11.8 .02
Male 201 (69) 52 (63) .25
EF (%) 55.9  10.8 52.4  12.7 .03
CHF 93 (32) 31 (37) .37
Diabetes 52 (18) 6 (7) .02
CPD 35 (12) 10 (12) 1.00
Hypertension 194 (67) 44 (53) .02
PVD 19 (7) 5 (6) 1.00
Additive EuroSCORE 5.7  2.7 5.0  2.3 .01
Duration of AF (mo) 41.3  56.0 41.9  50.6 .93
Type of AF
Long-standing persistent 154 (53) 48 (58) .45
Persistent 110 (38) 25 (30) .19
Paroxysmal/other 26 (9) 10 (12) .40
Full Cox-Maze 245 (85) 79 (95) .009
Minimally invasive 228 (79) 60 (72) .23
Cryothermia energy source 129 (45) 35 (42) .71
Concomitant CABG 87 (30) 16 (19) .054
Concomitant aortic valve 70 (24) 11 (13) .04
Concomitant mitral valve 111 (38) 53 (64) <.001
AF, Atrial fibrillation; CABG, coronary artery bypass grafting; CHF, congestive heart
faillure; CPD, chronic pulmonary disease; EF, ejection fraction; EuroSCORE, Euro-
pean System for Cardiac Operative Risk Evaluation; LA, left atrium; PVD, peripheral
vascular disease.
FIGURE 1. Comparison of freedom from embolic stroke indicating no
difference between the LA groups (log rank ¼ 0.15, P ¼ .70). LA, Left
atrium.
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Univariate analysis using left atrial size as a continuous
variable (range, 2.2-11.0 cm; Figure 2) found that the
predicted probability of failure at 1 year was 43% greater
with each 1-cm increase in left atrial size (odds ratio [OR],
1.43; 95% confidence interval [CI], 1.06-1.92; P ¼ .02;
Figure 3). Predicted probability of failure at 1 year without
antiarrhythmic drugs was 30% greater with each 1-cm in-
crease in left atrial size (OR, 1.30; 95% CI, 1.02-1.65;
P¼ .03). Figure 4 displays the change in slope for the univar-
iate relationship between left atrial size and failure as left
atrial size increases. Of note, the slope between left atrial
size of 7.5 cm and 8 cm changes considerably for both failure
and failure without antiarrhythmic drugs at 1 year. In addi-
tion, the slope of the relationship with failure at 1 year ap-
pears to shift upward between 5 and 6 cm. This pointTABLE 2. Sinus rhythm outcomes
Small LA
(n ¼ 290)
Large LA
(n ¼ 83)
P
value
NSR – 1 y 270 (93) 71 (86) .04
NSR off AAD – 1 y 247 (85) 64 (77) .10
NSR – 2 y 174/193 (90) 51/60 (85) .35
NSR off AAD – 2 y 155/192 (81) 44/60 (73) .28
Cardioversion during follow-up 52 (18) 19 (23) .34
Warfarin – 1 y 94/284 (33) 31/79 (39) .35
Non-AF clinical indication 52/94 (55) 22/31 (71) .14
AAD, Antiarrhythmic drug; AF, atrial fibrillation; LA, left atrium; NSR, normal sinus
rhythm.
238 The Journal of Thoracic and Cardiovascular Surgindicates that LA groups based on a cut-point of 5.5 cm pre-
sents a reasonable group differentiation.
Multivariate analysis of all traditional predictors of
rhythm status (including left atrial size as a continuous
variable) indicated that the only significant predictors of
failure at 1 year were duration of AF in years (OR, 1.13;
95% CI, 1.05-1.22; P<.001) and number of concomitant
surgical procedures (OR, 1.74; 95% CI, 1.04-2.90;
P ¼ .03), but not left atrial size (OR, 1.28; 95% CI, 0.88-
1.87; P ¼ .20), type of ablation procedure (OR, 1.87;
95% CI, 0.36-9.72; P ¼ .46), or energy source (OR, 0.66;
95% CI, 0.27-1.60; P ¼ .36). Within the large LA group
only, multivariate analysis found that longer duration of
AF (years) was the only independent predictor for AF at 1
year (OR, 1.22; 95% CI, 1.01-1.47; P ¼ .04).FIGURE 2. Histogram demonstrating left atrial size (centimeters) distri-
bution across the sample.
ery c January 2014
FIGURE 3. Predicted probability of failure (AF) at 12 months (solid line)
and failure (AF or normal SR on antiarrhythmic medications) at 12 months
(dashed line) across left atrial size as a continuous variable.
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An enlarged LA does convey a decreased probability of
being in SR at 12 months. However, despite the decreased
likelihood of being in SR at 12 months, this group still
experienced a high rate of return to SR at 12 months
(86% in SR), as well as a relatively high rate of return to
SR without antiarrhythmic medications (77%). By 2 years
after the Cox-Maze procedure, the likelihood of being in SR
with and without medications was similar for both groups
(>85% and >73%, respectively). The postoperative
outcomes were comparable for both patient groups with
few complications incurred. Even the group of patients
with an exceedingly large LA (7.5 cm) obtained an
acceptable return to SR whether on or off antiarrhythmic
drugs. In addition, embolic stroke events were low in bothFIGURE 4. Change in slope for the univariate relationship between left
atrial size and failure shown in Figure 3.
The Journal of Thoracic and CaLA groups despite the majority of patients no longer antico-
agulated at 12 months post-surgery.
Patients with a larger LAwere found to have significantly
more mitral valve disease. This observation has been
described in previous studies15,16 in which patients with
mitral valve disease who had on average an LA greater
than 5.5 cm experienced excellent outcomes after surgical
ablation. Researchers have also found that patients who
have their AF addressed at the time of surgery have better
long-term survival when compared with patients in whom
AF was not addressed at the time of surgery.17
In the multivariate analysis for the large LA group, the
only predictor for failure to establish SR at 12 months
was the duration of AF. This finding is congruent with
others who have reported on the failure of the Cox-Maze
procedure or surgical ablation because duration of AF is
closely associated with the development of atrial substrate
modification. Qian and colleagues,18 when investigating
the occurrence of AF with mitral valve disease, found that
the LA in this group of patients had a significantly greater
amount of fibrosis than those who presented with mitral
valve disease only.
Schotten and colleagues19 have been studying the
translational approach to the pathophysiologic mechanisms
of AF. They have found that atrial remodeling, which occurs
as a result of the electrical, contractile, and structural changes
within the atria, starts early even before the first episode of
AF occurs. They have recommended an individual early
intervention approach based on the numerous pathophysio-
logic processes that take place when AF occurs.19 In a pro-
spective study of 263 patients undergoing operation for
mitral valve disease and AF, Gillinov and co-investigators9
determined that the durationofAFwas a significant predictor
of failure of the Cox-Maze procedure.9 They concluded that
earlier intervention also was warranted in those with AF and
mitral valve disease to increase the chance of SR restoration
and to decrease the chance for AF recurrence.
Because of the different substrate changes associated
with mitral valve disease and subsequently the development
of AF, atrial tachyarrhythmias can be an issue after the
Cox-Maze procedure. Saint and colleagues15 studied this
phenomenon and found that patients who had mitral valve
disease and AF and underwent mitral valve surgery and a
Cox-Maze procedure had more tachyarrhythmias in the first
few months after surgery, but by 12 months their results
were similar to those of patients who had a Cox-Maze
procedure for lone AF. We found that the majority of
patients with a large LA had mitral valve disease and a
lower return to SR at 1 year off antiarrhythmic drugs, but
by 2 years the rate of return to SR was the same as the
patients without an enlarged LA, suggesting possible
reversal of the atrial remodeling.
Sunderland and colleagues10 recently published a best
evidence article on what size of the LA impairs the successrdiovascular Surgery c Volume 147, Number 1 239
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422 articles, with 12 studies that met all the criteria related
to the research question, they found that the significant
cutoff point for the success of a surgical ablation procedure
was 6.0 cm. They recommended caution be exercised when
offering a surgical ablation procedure to patients with an
LA greater than 6.0 cm. They also found, as various models
of AF suggest, that reducing atrial mass or diameter may
improve the outcome of surgical ablation by abolishing
the potential for reentry circuits and recurrence of AF.
Furthermore, because it was uncommon to find surgical
patients with a left atrial diameter less than 4 cm, the
physiologic basis for atrial reduction surgery is supported
in aiding the success of a Cox-Maze procedure. The
evidence suggests that patients with an enlarged LA who
are at higher risk of failure after standard surgical ablation
procedures may gain benefit from concomitant atrial
reduction surgery. However, the evidence is not strong
enough because all the studies are lacking a comparable
group with no left atrial reduction procedure, and there
are significant variations in the populations and procedures
involved. Therefore, there is a need for prospective
randomized studies in this area.
We also found that the rate of failure increased when the
LAwas greater than 5.5 cm, although this was only signif-
icant at 1 year. In addition, an encouraging finding in our
study was that the patients with an LA 7.5 cm or greater
had a high rate of return to SR. This finding warrants further
study especially because the majority of our patient popula-
tion underwent the full Cox-Maze procedure, and the report
by Sunderland and colleagues10 included different surgical
ablation procedures, ranging from a limited left-sided only
ablation to the full Cox-Maze procedure.
We believe a confounding factor in this study relates to
our thinking that AF is a chronic disease that requires close
lifelong follow-up. In line with this philosophy, we
developed a clinical protocol to treat patients after a surgical
ablation procedure.20 Our protocol addresses patients who
have returned to SR and the timely discontinuation of
their antiarrhythmic and anticoagulation therapy when
warranted. The protocol also addresses any recurrence of
atrial arrhythmia appropriately through medical therapy
or further intervention to obtain SR. Details on our protocol
and its impact on the restoration of SR after the Cox-Maze
procedure or surgical ablation have been published.2,21,22
We believe that using a follow-up protocol is essential
in assessing and monitoring for the recurrence of atrial
arrhythmias and addressing issues associated with anticoa-
gulation. Our experience shows that the clinical protocol is
safe and effective, resulting in improved outcomes. There-
fore, it is important to implement and use such protocols
in patients who are more prone to have failure after surgical
ablation for AF, such as the subgroup of patients with
increased left atrial size.240 The Journal of Thoracic and Cardiovascular SurgStudy Limitations
This is a single-center study in which more than
700 surgical ablation procedures have been performed by
experienced surgeons. These results may not be replicated
in centers with a lower patient volume.CONCLUSIONS
The large LA group (>5.5 cm) had an acceptable rate
of SR restoration overall and without antiarrhythmic
medications. Embolic stroke events were low in both
groups despite the majority of patients no longer taking
anticoagulation medication. If patients are managed
appropriately after surgical ablation, acceptable results
can be expected with the added advantage of lower risk of
stroke and need for anticoagulation. Our findings suggest
that left atrial size should not be a discouragement when
evaluating a surgical candidate with AF.
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